Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Innate Pharma, Novo Nordisk develop cancer immunotherapy

Executive Summary

Innate Pharma SAS (anticancer immunotherapy based on nonconventional lymphocytes) licensed Novo Nordisk AS exclusive research, development, and commercialization rights to a new class of immunomodulatory antibodies based on a family of receptor targets expressed by natural killer (NK) cells.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register